Shree Ganesh Remedies Ltd (SGRL) is currently trading at 625.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Shree Ganesh Remedies Limited manufactures pharmaceutical intermediates, specialty and fine chemicals for domestic and export markets, operating multi‑block manufacturing plants at Ankleshwar with pilot and R&D facilities, and pursuing larger automated projects at Dahej to serve global pharmaceutical clients and custom synthesis (CRAMS) demands. Q1FY27 was materially weak: revenue of ₹14.36 crore, down 42% YoY and 57% QoQ, EBITDA fell 54% YoY to ₹3.35 crore and PAT dropped 68% YoY; management attributes the decline to subdued European demand, distributor termination and raw material volatility, with a moderated FY27 outlook and recovery expected in H2FY27. The company is actively shifting mix toward patented, customer‑specific molecules expected to exceed 60% of revenues in the medium term, supported by DSIR‑recognised R&D, pilot plant scale‑ups, high‑pressure reactors and advanced chemistries that differentiate Shree Ganesh Remedies Limited from commodity intermediates producers. Strategic assets include a commissioned 2.5 MW solar park covering up to 70% of electricity needs, a DSIR‑recognised R&D lab with HPC capabilities and a 40,554 sq m land parcel at Dahej reserved for phased large‑scale, capital‑intensive projects, positioning the company for higher automation and scale.

Over the past 52 weeks, Shree Ganesh Remedies Ltd has traded between a low of ₹381.10 and a high of ₹759.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Shree Ganesh Remedies Ltd has a market capitalization of approximately 803.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Shree Ganesh Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 52.02 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 803.25 Cr, Shree Ganesh Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Shree Ganesh Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Shree Ganesh Remedies Ltd is 52.02. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Net profit after tax (PAT) was ₹1.12 crore for the quarter ended June 30, 2026, down 67.5% year-on-year from ₹3.45 crore.